Savara (SVRA) Depreciation & Amortization (CF) (2010 - 2026)
Savara (SVRA) posted quarterly Depreciation & Amortization (CF) of $24000.0 for Q1 2026, down 20.0% year-over-year from $30000.0 in Q1 2025, and up 318.18% quarter-over-quarter from -$11000.0 in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $24000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 20.0% year-over-year to $24000.0; the TTM figure through Mar 2026 stood at $81000.0 (down 36.72% YoY), while the FY2025 annual figure was $87000.0, down 33.08% from the prior year.
- Depreciation & Amortization (CF) grew to $24000.0 in Q1 2026 per SVRA's latest filing, from -$11000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $35000.0 in Q3 2025 and bottomed at -$11000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $20588.2 across 5 years, with a median of $30000.0 in 2023.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) jumped 357.14% — and 2025, when it tumbled 134.38%.
- Savara's Depreciation & Amortization (CF) stood at $7000.0 in 2022, then soared by 357.14% to $32000.0 in 2023, then changed by 0.0% to $32000.0 in 2024, then sank by 134.38% to -$11000.0 in 2025, then surged by 318.18% to $24000.0 in 2026.
- Business Quant data shows SVRA's Depreciation & Amortization (CF) at $24000.0 in Q1 2026, -$11000.0 in Q4 2025, and $35000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | 28,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Sep 30, 2022 | 8,000.00 |
| Jun 30, 2022 | 8,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 40,000.00 |